🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for ER Positive, HER2 Positive Breast Cancer

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. NCT07062965Phase 3433 sites📍 Anchorage📍 Chandler📍 Gilbert Pfizer · Tests: PF-07248144, Fulvestrant, Everolimus, Exemestane Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer NCT07214532NA49 sites📍 Phoenix📍 Scottsdale📍 Tucson Natera, Inc. · Tests: ctDNA-Guided Treatment Strategy Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) NCT06757634Phase 3239 sites📍 Jonesboro📍 Little Rock📍 Duarte Celcuity Inc · Tests: Arm A: Gedatolisib + Palbociclib + Fulvestrant, Arm B: Ribociclib + Fulvestrant, Arm C: Gedatolisib + Palbociclib + Let… Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib NCT06341621Phase 31 site📍 Shanghai Fudan University · Tests: 3-year abemaciclib without chemo, treatment of physician's choice PRE-ISPY Phase I/II Oncology Platform Program NCT05868226Phase 1, Phase 210 sites📍 Birmingham📍 Phoenix📍 Aurora QuantumLeap Healthcare Collaborative · Tests: ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab, Tucatinib, TTX-MC138 Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC NCT06500208Phase 21 site📍 Shanghai Shanghai Jiao Tong University School of Medicine · Tests: Adebrelimab combined with nab-paclitaxel, epirubicin and cyclophosphamide Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) NCT05512364Phase 3113 sites📍 Anderlecht📍 Brussels📍 Brussels European Organisation for Research and Treatment of Cancer … · Tests: Elacestrant, Tamoxifen, Letrozole 2.5mg, Anastrozole 1mg, Exemestane 25 MG Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery NCT06450873Phase 21 site📍 Scottsdale Mayo Clinic · Tests: Coriolus Versicolor Extract, Questionnaire Administration Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer NCT07427394Phase 26 sites📍 St Louis📍 East Providence📍 Nashville AstraZeneca · Tests: Camizestrant, Atirmociclib Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer NCT05386108Phase 1, Phase 286 sites📍 Fullerton📍 Los Angeles📍 Urbana Stemline Therapeutics, Inc. · Tests: Elacestrant, Abemaciclib Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers NCT05846789Phase 27 sites📍 Atlanta📍 Carmel📍 Indianapolis Kathy Miller · Tests: SOC Chemotherapy, Tocilizumab/Tocilizumab Biosimilar Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy NCT02945579NA8 sites📍 Gilbert📍 Jacksonville📍 Honolulu M.D. Anderson Cancer Center · Tests: Undergo EBRT, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration, Partial Breast I… TCb vs EC-T in High Risk ER+/HER2- Breast Cancer NCT05901428Phase 31 site📍 Shanghai Fudan University · Tests: Docetaxel, Carboplatin, Epirubicin, Cyclophosphamide Omission of Adjuvant Radiotherapy in Low- and Intermediate-Risk Ductal Carcinoma In Situ After Breast-Conserving Surgery NCT07762885Phase 31 site📍 Shanghai Fudan University · Tests: Adjuvant Radiotherapy, tamoxifen Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer NCT06525766Phase 21 site📍 Scottsdale Mayo Clinic · Tests: Biospecimen Collection, Bone Scan, Capecitabine, Computed Tomography, Magnetic Resonance Imaging S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer NCT03723928NA723 sites📍 Anchorage📍 Anchorage📍 Anchorage SWOG Cancer Research Network · Tests: Usual care disease monitoring, Serum Tumor Marker directed disease monitoring, Quality-of-Life Assessment, Anxiety Ques… Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer NCT06062498Phase 23 sites📍 Chicago📍 Chicago📍 Chicago Northwestern University · Tests: elacestrant, palbociclib, abemaciclib, ribociclib A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence NCT06492616Phase 3567 sites📍 Daphne📍 Chandler📍 Gilbert Stemline Therapeutics, Inc. · Tests: Elacestrant, Anastrozole, Letrozole, Exemestane, Tamoxifen To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer NCT04660435n/a1 site📍 Prato Fondazione Sandro Pitigliani · Tests: Thymidine kinase activity Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer NCT05020860Phase 22 sites📍 Houston📍 Houston Baylor Breast Care Center · Tests: Paclitaxel, Carboplatin, Trastuzumab, Pertuzumab, Doxorubicin Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer NCT07085767Phase 3200 sites📍 Hot Springs📍 Beverly Hills📍 La Jolla Olema Pharmaceuticals, Inc. · Tests: Palazestrant, Letrozole-matching placebo, Ribociclib, Letrozole, Palazestrant matching-placebo A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery NCT06127979NA1 site📍 New York Memorial Sloan Kettering Cancer Center · Tests: blood draw Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC NCT06263543Phase 23 sites📍 Miami📍 Atlanta📍 Fairway Reshma L. Mahtani, D.O. · Tests: Sacituzumab govitecan NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline NCT06452394Phase 28 sites📍 Sankt Gallen📍 Genolier📍 Winterthur Swiss Cancer Institute · Tests: Doxycyclin Elacestrant in Advanced Triple Positive Breast Cancer NCT07612215Phase 1, Phase 21 site📍 New York NYU Langone Health · Tests: Elacestrant, Trastuzumab, Pertuzumab Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial NCT07391774Phase 3232 sites📍 Jonesboro📍 Auburn📍 Berkeley National Cancer Institute (NCI) · Tests: Anastrozole, Biospecimen Collection, Bone Scan, Chemotherapy, Computed Tomography Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 NCT05879926Phase 31261 sites📍 Birmingham📍 Anchorage📍 Anchorage NRG Oncology · Tests: Ovarian Function Suppression + Aromatase Inhibitor, Adjuvant Chemotherapy + Ovarian Function Suppression Capecitabine in ER+/HER2-negative Breast Cancer NCT07631052Phase 21 site📍 Toronto University Health Network, Toronto · Tests: Capecitabine A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors NCT07318805Phase 113 sites📍 Duarte📍 Grand Rapids📍 Long Island City Pfizer · Tests: PF-08032562, Fulvestrant, Cetuximab, Fluorouracil, Oxaliplatin Efficacy and Safety of Culmerciclib Plus Aromatase Inhibitors in a Response-Adapted Neoadjuvant Strategy for Highly Proliferative ER-Positive/HER2-Negative Breast Cancer NCT07616453Phase 21 site📍 Hangzhou Second Affiliated Hospital, Zhejiang University, School of … · Tests: Culmerciclib, Aromatase Inhibitors
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy